U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Pfizer Global Medical Grants & Partnerships is pleased to announce the latest grant opportunity with colleagues focused on Increasing Awareness & Understanding of Emerging Hemophilia Treatment ...

Pfizer and GITAM University empower rural women with employment through Pfizer autonomous teams programme: Our Bureau, Bengaluru Friday, May 23, 2025, 13:30 Hrs [IST] Pfizer Globa ...

To increase women representation in the pharmaceutical industry, Pfizer Global Supply’s manufacturing unit in Visakhapatnam ...

Pfizer Inc. announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc., a leading Chinese biopharmaceutical company, for the development, manufacturing and ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

3SBio, along with its subsidiaries Shenyang Sunshine Pharmaceutical and 3S Guojian Pharmaceutical (Shanghai), will grant Pfizer exclusive global rights to SSGJ-707 outside of China. Pfizer retains ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

3SBio, along with its subsidiaries Shenyang Sunshine Pharmaceutical and 3S Guojian Pharmaceutical (Shanghai), will grant Pfizer exclusive global rights to SSGJ-707 outside of China. Pfizer retains the ...

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a ...